Clinical Research Studies

Atherosclerotic cardiovascular disease (ACVD) is driven by inflammation and is the leading cause of mortality and disability worldwide, even in optimally treated patients. The impact of many immune cells (inflammatory cells) on atherosclerosis progression is well-established, the contribution of different immune and non-immune cells to human disease pathology and cardiovascular (CV) events remain largely unknown. It is well established that specific histological features of plaque instability are associated with increased risk for cardiovascular events (i.e. stroke, heart attack). This study will address the following knowledge gaps. The ATHERO-IN study is a prospective and retrospective, multisite, observational study. The study will be conducted at two study sites: 1. the NYU Langone Health (coordinating and recruitment site) and 2. the Icahn School of Medicine at Mount Sinai (recruitment site). The Focus of the study is atherosclerotic cardiovascular disease and inflammation. The Goal of the study is to identify new cellular and molecular determinant of atherosclerosis, plaque pathology and cardiovascular events. To achieve this goal, we will use a system biology approach to analyze human samples that will be obtained from patients with atherosclerotic cardiovascular disease from the NYU Langone Health System (NYULH) and from the Mount Sinai Health System (MSHS).